Search Results - "Liva, Sophia G."

Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor by Liva, Sophia G, Tseng, Yu‐Chou, Dauki, Anees M, Sovic, Michael G, Vu, Trang, Henderson, Sally E, Kuo, Yi‐Chiu, Benedict, Jason A, Zhang, Xiaoli, Remaily, Bryan C, Kulp, Samuel K, Campbell, Moray, Bekaii‐Saab, Tanios, Phelps, Mitchell A, Chen, Ching‐Shih, Coss, Christopher C

“…No approved therapy exists for cancer‐associated cachexia. The colon‐26 mouse model of cancer cachexia mimics recent late‐stage clinical failures of anabolic…”
Get full text

Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study by Taylor, Peter C, Schett, Georg, Huizinga, Tom WJ, Wang, Qingmin, Ibrahim, Fowzia, Zhou, Bei, Liva, Sophia G, Shaik, Jafar Sadik B, Xiong, Yuan, Leu, Jocelyn H, Panchakshari, Rohit A, Loza, Matthew J, Ma, Keying, Dhatt, Harman, Rojo Cella, Ricardo, Karyekar, Chetan S, Cuff, Carolyn A, Gao, Sheng, Fei, Kaiyin

“…ObjectivesTo investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of nipocalimab in participants with moderate to severe active rheumatoid…”
Get full text

Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans by Castillo, Alyssa Marie M., Vu, Trang T., Liva, Sophia G., Chen, Min, Xie, Zhiliang, Thomas, Justin, Remaily, Bryan, Guo, Yizhen, Subrayan, Uma L., Costa, Travis, Helms, Timothy H., Irby, Donald J., Kim, Kyeongmin, Owen, Dwight H., Kulp, Samuel K., Mace, Thomas A., Phelps, Mitch A., Coss, Christopher C.

“…Background Monoclonal antibody (mAb) immune checkpoint inhibitor (ICI) therapies have dramatically impacted oncology this past decade. However, only about…”
Get full text

Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review by Xu, Zhenhua, Leu, Jocelyn H., Xu, Yan, Nnane, Ivo, Liva, Sophia G., Wang‐Lin, Shun Xin, Kudgus‐Lokken, Rachel, Vermeulen, An, Ouellet, Daniele

“…Therapeutic proteins may first be developed as intravenous (i.v.) therapies with new subcutaneous (s.c.) dosage forms being subsequently developed to provide…”
Get full text

A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies by Collier, Katharine A., Valencia, Hugo, Newton, Herbert, Hade, Erinn M., Sborov, Douglas W., Cavaliere, Robert, Poi, Ming, Phelps, Mitch A., Liva, Sophia G., Coss, Christopher C., Wang, Jiang, Khountham, Soun, Monk, Paul, Shapiro, Charles L., Piekarz, Richard, Hofmeister, Craig C., Welling, D. Bradley, Mortazavi, Amir

“…Purpose Given clinical activity of AR-42, an oral histone deacetylase inhibitor, in hematologic malignancies and preclinical activity in solid tumors, this…”
Get full text

Phase I study of AR-42 and decitabine in acute myeloid leukemia by Liva, Sophia G., Coss, Christopher C., Wang, Jiang, Blum, William, Klisovic, Rebecca, Bhatnagar, Bhavana, Walsh, Katherine, Geyer, Susan, Zhao, Qiuhong, Garzon, Ramiro, Marcucci, Guido, Phelps, Mitch A., Walker, Alison R.

“…This phase I trial sought to determine a biologically safe and effective dose of AR-42, a novel histone deacetylase inhibitor, which would lead to a doubling…”
Get full text